IL25 and breast carcinoma: Encouragingly, IL25 monoclonal antibody XKH001 was the first IL25 inhibitor which was approved by the FDA in 2021 for the clinical trial of inflammatory associated diseases, and IL25 blockade inhibited lung metastasis in breast cancer (19).